Catalent Inc. said it will provide vial filling and packaging
capacity to AstraZeneca PLC at Catalent’s manufacturing facility in
Anagni, Italy, and prepare for large-scale commercial supply of the
University of Oxford’s Covid-19 vaccine candidate, AZD1222.
Catalent shares were up 11% to $77 premarket.
The agreement accelerates the rapid scale-up of capacity over the
coming months to support the dedicated production of AZD1222, the
provider of advanced delivery technologies, development, and
manufacturing solutions for drugs.
Catalent said it will prepare the facility to enable manufacturing
schedules and supply hundreds of millions of doses of the vaccine
candidate from August 2020, and potentially through to March 2022 if the
product is approved by regulatory agencies.
https://www.marketscreener.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Catalent-in-Agreement-with-AstraZeneca-to-Manufacture-Covid-19-Vaccine-Candidate-30771704/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.